Wojciech Zareba

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9166572/publications.pdf

Version: 2024-02-01

241 papers	24,916 citations	31902 53 h-index	6818 155 g-index
241 all docs	241 docs citations	241 times ranked	12713 citing authors

#	Article	IF	Citations
1	Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. New England Journal of Medicine, 2002, 346, 877-883.	13.9	6,199
2	Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. New England Journal of Medicine, 2009, 361, 1329-1338.	13.9	2,716
3	Genotype-Phenotype Correlation in the Long-QT Syndrome. Circulation, 2001, 103, 89-95.	1.6	1,641
4	Reduction in Inappropriate Therapy and Mortality through ICD Programming. New England Journal of Medicine, 2012, 367, 2275-2283.	13.9	1,186
5	Effectiveness and Limitations of Î²-Blocker Therapy in Congenital Long-QT Syndrome. Circulation, 2000, 101, 616-623.	1.6	783
6	Influence of the Genotype on the Clinical Course of the Long-QT Syndrome. New England Journal of Medicine, 1998, 339, 960-965.	13.9	728
7	Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trialâ€“Cardiac Resynchronization Therapy (MADIT-CRT). Circulation, 2011, 123, 1061-1072.	1.6	714
8	Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome. Circulation, 2004, 109, 1826-1833.	1.6	600
9	ECG T-Wave Patterns in Genetically Distinct Forms of the Hereditary Long QT Syndrome. Circulation, 1995, 92, 2929-2934.	1.6	501
10	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.3	494
11	Age- and Sex-Related Differences in Clinical Manifestations in Patients With Congenital Long-QT Syndrome. Circulation, 1998, 97, 2237-2244.	1.6	451
12	Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-goâ€“Related Gene Potassium Channel. Circulation, 2002, 105, 794-799.	1.6	370
13	Long QT Syndrome and Pregnancy. Journal of the American College of Cardiology, 2007, 49, 1092-1098.	1.2	299
14	Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure. New England Journal of Medicine, 2014, 370, 1694-1701.	13.9	283
15	Implantable Cardioverter Defibrillator in Highâ€Risk Long QT Syndrome Patients. Journal of Cardiovascular Electrophysiology, 2003, 14, 337-341.	0.8	280
16	Predictors of Response to Cardiac Resynchronization Therapy in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT). Circulation, 2011, 124, 1527-1536.	1.6	275
17	Risk of Aborted Cardiac Arrest or Sudden Cardiac Death During Adolescence in the Long-QT Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1249.	3.8	258
18	Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. Journal of the American College of Cardiology, 2003, 42, 103-109.	1.2	257

#	Article	IF	Citations
19	Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome. Circulation, 2008, 117, 2184-2191.	1.6	255
20	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. European Heart Journal, 2020, 41, 1414-1429.	1.0	239
21	An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation, 2020, 141, 418-428.	1.6	238
22	Genotype-Phenotype Aspects of Type 2 Long QT Syndrome. Journal of the American College of Cardiology, 2009, 54, 2052-2062.	1.2	236
23	Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2015, 36, 1735-1743.	1.0	236
24	Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events. Circulation, 2012, 125, 1988-1996.	1.6	187
25	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. European Heart Journal, 2018, 39, 2314-2325.	1.0	186
26	Clinical Aspects of Type 3 Long-QT Syndrome. Circulation, 2016, 134, 872-882.	1.6	162
27	Ventricular Arrhythmias in the North American Multidisciplinary Study of ARVC. Journal of the American College of Cardiology, 2014, 64, 119-125.	1.2	156
28	Left Ventricular Ejection Fraction Normalization in Cardiac Resynchronization Therapy and Risk of Ventricular Arrhythmias and Clinical Outcomes. Circulation, 2014, 130, 2278-2286.	1.6	153
29	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.3	135
30	Long-QT Syndrome After Age 40. Circulation, 2008, 117, 2192-2201.	1.6	134
31	Risk of cardiac events in family members of patients with long QT syndrome. Journal of the American College of Cardiology, 1995, 26, 1685-1691.	1.2	129
32	The HARMONY Trial. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1048-1056.	2.1	129
33	Mutation and gender-specific risk in type 2 long QT syndrome: Implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm, 2011, 8, 1537-1543.	0.3	117
34	Normalization of Ventricular Repolarization with Flecainide in Long QT Syndrome Patients with SCN5A:?KPQ Mutation. Annals of Noninvasive Electrocardiology, 2001, 6, 153-158.	0.5	110
35	Clinical Course and Implantable Cardioverter Defibrillator Therapy in Postinfarction Women with Severe Left Ventricular Dysfunction. Journal of Cardiovascular Electrophysiology, 2005, 16, 1265-1270.	0.8	105
36	Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure. JAMA Cardiology, 2020, 5, 300.	3.0	104

#	Article	IF	Citations
37	Arrhythmogenic Phenotype in Dilated Cardiomyopathy: Natural History and Predictors of Lifeâ€Threatening Arrhythmias. Journal of the American Heart Association, 2015, 4, e002149.	1.6	102
38	Mortality Reduction in Relation to Implantable Cardioverter Defibrillator Programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circulation: Arrhythmia and Electrophysiology, 2014, 7, 785-792.	2.1	101
39	Betaâ€Blocker Efficacy in Highâ€Risk Patients with the Congenital Longâ€QT Syndrome Types 1 and 2: Implications for Patient Management. Journal of Cardiovascular Electrophysiology, 2010, 21, 893-901.	0.8	99
40	Antipsychotic drugs and QT interval prolongation. Psychiatric Quarterly, 2003, 74, 291-306.	1.1	96
41	High interobserver variability in the assessment of epsilon waves: Implications for diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm, 2016, 13, 208-216.	0.3	76
42	Long QT Syndrome and Short QT Syndrome. Progress in Cardiovascular Diseases, 2008, 51, 264-278.	1.6	75
43	Clinical Implications for Affected Parents and Siblings of Probands With Long-QT Syndrome. Circulation, 2001, 104, 557-562.	1.6	71
44	Location of Mutation in the KCNQ1 and Phenotypic Presentation of Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 2003, 14, 1149-1153.	0.8	69
45	Risk of Recurrent Cardiac Events After Onset of Menopause in Women With Congenital Long-QT Syndrome Types 1 and 2. Circulation, 2011, 123, 2784-2791.	1.6	69
46	The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. European Heart Journal, 2015, 36, 440-448.	1.0	68
47	Prediction of sudden and non-sudden cardiac death in post-infarction patients with reduced left ventricular ejection fraction by periodic repolarization dynamics: MADIT-II substudy. European Heart Journal, 2017, 38, 2110-2118.	1.0	68
48	Multicenter Automatic Defibrillator Implantation Trial II (MADIT II): Design and Clinical Protocol. Annals of Noninvasive Electrocardiology, 1999, 4, 83-91.	0.5	61
49	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. European Heart Journal, 2021, 42, 1676-1684.	1.0	61
50	Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm, 2012, 9, 892-898.	0.3	58
51	Associations between ambient wood smoke and other particulate pollutants and biomarkers of systemic inflammation, coagulation and thrombosis in cardiac patients. Environmental Research, 2017, 154, 352-361.	3.7	58
52	Correlation Method for Detection of Transient T-Wave Alternans in Digital Holter ECG Recordings. Annals of Noninvasive Electrocardiology, 1999, 4, 416-424.	0.5	57
53	Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. European Heart Journal, 2022, 43, 1500-1510.	1.0	57
54	Implantable Cardioverter-Defibrillator Efficacy in Patients With Heart Failure and Left Ventricular Dysfunction (from the MADIT II Population). American Journal of Cardiology, 2005, 95, 1487-1491.	0.7	56

#	Article	IF	Citations
55	Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2018, 72, 636-645.	1.2	55
56	QT Dynamics and Variability. Annals of Noninvasive Electrocardiology, 2005, 10, 256-262.	0.5	52
57	Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. American Heart Journal, 2017, 189, 75-84.	1.2	52
58	Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. Heart Rhythm, 2006, 3, 631-637.	0.3	51
59	Association Between Frequency of Atrial and Ventricular Ectopic Beats and Biventricular Pacing Percentage and Outcomes in Patients With Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2014, 64, 971-981.	1.2	50
60	The Value of Electrocardiographic Abnormalities in the Prognosis of Pulmonary Embolism: A Consensus Paper. Annals of Noninvasive Electrocardiology, 2015, 20, 207-223.	0.5	50
61	Clinical Implications of Complete Left-Sided Reverse Remodeling With CardiacÂResynchronization Therapy. Journal of the American College of Cardiology, 2016, 68, 1268-1276.	1.2	47
62	Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADITâ€CRT) Trial. Journal of Cardiovascular Electrophysiology, 2015, 26, 862-871.	0.8	46
63	Elevated particle number concentrations induce immediate changes in heart rate variability: a panel study in individuals with impaired glucose metabolism or diabetes. Particle and Fibre Toxicology, 2015, 12, 7.	2.8	46
64	Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes. Journal of Molecular and Cellular Cardiology, 2016, 100, 25-34.	0.9	46
65	Genotype-specific ECG patterns in long QT syndrome. Journal of Electrocardiology, 2006, 39, S101-S106.	0.4	44
66	ECG Parameters and Exposure to Carbon Ultrafine Particles in Young Healthy Subjects. Inhalation Toxicology, 2009, 21, 223-233.	0.8	43
67	Asthma and the risk of cardiac events in the long QT syndrome. American Journal of Cardiology, 1999, 84, 1406-1411.	0.7	41
68	Apical vs. non-apical right ventricular pacing in cardiac resynchronization therapy: a meta-analysis. Europace, 2015, 17, 1259-1266.	0.7	41
69	Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up. Clinical Research in Cardiology, 2016, 105, 944-952.	1.5	41
70	Proposed Inâ€Training Electrocardiogram Interpretation Competencies for Undergraduate and Postgraduate Trainees. Journal of Hospital Medicine, 2018, 13, 185-193.	0.7	41
71	Noninvasive risk stratification in postinfarction patients with severe left ventricular dysfunction and methodology of the MADIT II noninvasive electrocardiology substudy. Journal of Electrocardiology, 2003, 36, 101-108.	0.4	40
72	An International Multicenter Evaluation of Type 5 Long QT Syndrome. Circulation, 2020, 141, 429-439.	1.6	39

#	Article	IF	Citations
73	Genetic biomarkers for the risk of seizures in long QT syndrome. Neurology, 2016, 87, 1660-1668.	1.5	38
74	Hybrid comprehensive telerehabilitation in heart failure patients (TELEREH-HF): A randomized, multicenter, prospective, open-label, parallel group controlled trialâ€"Study design and description of the intervention. American Heart Journal, 2019, 217, 148-158.	1.2	38
75	Sex Differences in Longâ€Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block. Journal of the American Heart Association, 2015, 4, .	1.6	37
76	Clinical Presentation and Outcomes by Sex in Arrhythmogenic Right Ventricular Cardiomyopathy: Findings from the North American ARVC Registry. Journal of Cardiovascular Electrophysiology, 2016, 27, 555-562.	0.8	37
77	Multiple Comorbidities and Response to Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2017, 69, 2369-2379.	1.2	37
78	A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology. Heart Rhythm, 2008, 5, 11-18.	0.3	33
79	Clinical aspects of the three major genetic forms of long <scp>QT</scp> syndrome (<scp>LQT</scp>1,) Tj ETQq1 1 0.784314 rgBT /Ov	0.5	33
80	Negative T Wave in Ischemic Heart Disease: A Consensus Article. Annals of Noninvasive Electrocardiology, 2014, 19, 426-441.	0.5	32
81	Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. JAMA - Journal of the American Medical Association, 2019, 322, 1799.	3.8	32
82	Ambient and controlled exposures to particulate air pollution and acute changes in heart rate variability and repolarization. Scientific Reports, 2019, 9, 1946.	1.6	32
83	Risk of Cardiac Events in Patients With Asthma and Long-QT Syndrome Treated With Beta2 Agonists. American Journal of Cardiology, 2008, 102, 871-874.	0.7	31
84	The Effect of ICD Programming on Inappropriate and Appropriate ICD Therapies in Ischemic and Nonischemic Cardiomyopathy: The MADITâ€RIT Trial. Journal of Cardiovascular Electrophysiology, 2015, 26, 424-433.	0.8	31
85	Multicenter Automatic Defibrillator Implantation Trialâ€"Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. American Heart Journal, 2017, 189, 158-166.	1.2	31
86	Atrial Fibrillation in Long QT Syndrome by Genotype. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007213.	2.1	31
87	The Effect of Intermittent Atrial Tachyarrhythmia on Heart Failure or Death inÂCardiac Resynchronization Therapy WithÂDefibrillator Versus Implantable Cardioverter-Defibrillator Patients. Journal of the American College of Cardiology, 2014, 63, 1190-1197.	1.2	28
88	Reduced Irregularity of Ventricular Response During Atrial Fibrillation and Long-term Outcome in Patients WithÂHeartÂFailure. American Journal of Cardiology, 2015, 116, 1071-1075.	0.7	28
89	Longâ€QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder. Journal of Cardiovascular Electrophysiology, 2015, 26, 1039-1044.	0.8	27
90	Gene-Specific Therapy for Long QT Syndrome.. Annals of Noninvasive Electrocardiology, 1997, 2, 274-278.	0.5	26

#	Article	IF	Citations
91	Early Procedureâ€Related Adverse Events by Gender in MADITâ€CRT. Journal of Cardiovascular Electrophysiology, 2014, 25, 985-989.	0.8	26
92	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). Europace, 2022, 24, 614-619.	0.7	26
93	NAD(P)H oxidase polymorphism (C242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients. Atherosclerosis, 2008, 196, 461-468.	0.4	25
94	Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial. Heart Rhythm, 2015, 12, 2010-2017.	0.3	25
95	Predictors of Spontaneous Reverse Remodeling in Mild Heart Failure Patients With Left Ventricular Dysfunction. Circulation: Heart Failure, 2014, 7, 565-572.	1.6	24
96	Cardiovascular function and ozone exposure: The Multicenter Ozone Study in oldEr Subjects (MOSES). Environment International, 2018, 119, 193-202.	4.8	24
97	Reduced risk of lifeâ€threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction. European Journal of Heart Failure, 2015, 17, 971-978.	2.9	23
98	Effect of Gender on the Risk of Neurologic Events and Subsequent Outcomes in Patients With Left Ventricular Assist Devices. American Journal of Cardiology, 2017, 119, 297-301.	0.7	22
99	Primary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients. Europace, 2019, 21, 339-346.	0.7	22
100	Improving Clinical Practice Guidelines for Practicing Cardiologists. American Journal of Cardiology, 2015, 115, 1773-1776.	0.7	21
101	Does total antioxidant capacity modify adverse cardiac responses associated with ambient ultrafine, accumulation mode, and fine particles in patients undergoing cardiac rehabilitation?. Environmental Research, 2016, 149, 15-22.	3.7	20
102	Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. JACC: Clinical Electrophysiology, 2018, 4, 1410-1420.	1.3	20
103	Stop-codon and C-terminal nonsense mutations are associated with a lower risk of cardiac events in patients with long QT syndrome type 1. Heart Rhythm, 2016, 13, 122-131.	0.3	19
104	JT interval: What does this interval mean?. Journal of Electrocardiology, 2017, 50, 748-751.	0.4	19
105	Ventricular Electrical Delay Measured From Body Surface ECGs Is Associated With Cardiac Resynchronization Therapy Response in Left Bundle Branch Block Patients From the MADIT-CRT Trial (Multicenter Automatic Defibrillator Implantation-Cardiac Resynchronization Therapy). Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005719.	2.1	19
106	Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction. Circulation: Heart Failure, 2015, 8, 725-732.	1.6	18
107	Impaired IKs channel activation by Ca2+-dependent PKC shows correlation with emotion/arousal-triggered events in LQT1. Journal of Molecular and Cellular Cardiology, 2015, 79, 203-211.	0.9	17
108	Automatic QRS Selvester scoring system in patients with left bundle branch block. Europace, 2016, 18, 308-314.	0.7	17

#	Article	IF	Citations
109	Risk Stratification of Type 2 Long-QT Syndrome Mutation Carriers With Normal QTc Interval. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005918.	2.1	17
110	QTâ€RR Slope:. Journal of Cardiovascular Electrophysiology, 2003, 14, 234-235.	0.8	16
111	Acute changes in ambient temperature are associated with adverse changes in cardiac rhythm. Air Quality, Atmosphere and Health, 2014, 7, 357-367.	1.5	16
112	Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. Europace, 2015, 17, 1085.1-1091.	0.7	16
113	Left Ventricular Reverse Remodeling in Cardiac Resynchronization Therapy and Long-TermÂOutcomes. JACC: Clinical Electrophysiology, 2019, 5, 1001-1010.	1.3	16
114	Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block. Circulation: Heart Failure, 2016, 9, e002667.	1.6	15
115	Oneâ€year followâ€up of the prospective registry of patients using the wearable defibrillator (WEARITâ€ℍ) Tj ETQq1 1 0.784314 rgBT /O	0.5	15
116	Heart Rate Variability in Patients with Congenital Long QT Syndrome. Annals of Noninvasive Electrocardiology, 2001, 6, 298-304.	0.5	14
117	Comparison of Age (<75ÂYears Versus â‰¥75ÂYears) to Risk of Ventricular Tachyarrhythmias and Implantable Cardioverter Defibrillator Shocks (from the Multicenter Automatic Defibrillator) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T f 5 114, 1855-1860.	0.7	14
118	Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events. Cardiovascular Diabetology, 2016, 15, 93.	2.7	14
119	Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century. Journal of Physiology, 2016, 594, 6893-6908.	1.3	14
120	Predictive value of device-derived activity level for short-term outcomes in MADIT-CRT. Heart Rhythm, 2017, 14, 1081-1086.	0.3	14
121	Effectiveness of Implantable Cardioverter-Defibrillators to ReduceÂMortality in Patients With LongÂQT Syndrome. Journal of the American College of Cardiology, 2021, 78, 2076-2088.	1.2	14
122	Dispersion of Repolarization: Time to Move Beyond QT Dispersion. Annals of Noninvasive Electrocardiology, 2000, 5, 373-381.	0.5	12
123	The Effect of Weight Loss on Clinical Outcomes in Patients Implanted With a Cardiac Resynchronization Therapy Deviceâ€"A MADIT-CRT Substudy. Journal of Cardiac Failure, 2014, 20, 183-189.	0.7	12
124	Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapyâ€defibrillator patients: a <scp>MADIT</scp>â€<scp>CRT</scp> substudy. Annals of Noninvasive Electrocardiology, 2018, 23, e12491.	0.5	12
125	A counterpoint paper: Comments on the electrocardiographic part of the 2018 Fourth Universal Definition of Myocardial Infarction. Journal of Electrocardiology, 2020, 60, 142-147.	0.4	12
126	Reassessing the role of antitachycardia pacing in fast ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: Results from MADIT-RIT. Heart Rhythm, 2021, 18, 399-403.	0.3	12

#	Article	IF	Citations
127	Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary ICD Therapy. JACC: Clinical Electrophysiology, 2022, 8, 1-11.	1.3	12
128	A Metric for Evaluating the Cardiac Response to ResynchronizationÂTherapy. American Journal of Cardiology, 2014, 113, 1371-1377.	0.7	11
129	Early intervention and longâ€term outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptoms. European Journal of Heart Failure, 2015, 17, 964-970.	2.9	11
130	Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT. Europace, 2015, 17, 1816-1822.	0.7	11
131	Bipolar left ventricular pacing is associated with significant reduction in heart failure or death in CRT-D patients with LBBB. Heart Rhythm, 2016, 13, 1468-1474.	0.3	11
132	Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT. Heart Rhythm, 2016, 13, 852-859.	0.3	11
133	Long-Term Survival of Patients With Left Bundle Branch Block Who Are Hypo-Responders to Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 120, 825-830.	0.7	11
134	Abnormal Repolarization Duration During Everyday Emotional Arousal in Long QT Syndrome and Coronary Artery Disease. American Journal of Medicine, 2018, 131, 565-572.e2.	0.6	11
135	Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator. Heart Rhythm, 2018, 15, 1379-1386.	0.3	11
136	Prognostic Significance of Heart Rate Variability Among Patients Treated With Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2015, 1, 74-80.	1.3	10
137	Inverse Relationship of Blood Pressure to Long-Term Outcomes and Benefit of Cardiac Resynchronization Therapy in Patients With Mild Heart Failure. Circulation: Heart Failure, 2015, 8, 921-926.	1.6	10
138	Characterization and predictors of first and subsequent inappropriate ICD therapy by heart rate ranges: Result of the MADIT-RIT efficacy analysis. Heart Rhythm, 2015, 12, 2030-2037.	0.3	10
139	Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure. American Journal of Cardiology, 2018, 121, 615-620.	0.7	10
140	Quality of life in heart failure patients undergoing hybrid comprehensive telerehabilitation versus usual care â€“ results of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial. Archives of Medical Science, 2020, 17, 1599-1612.	0.4	10
141	Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial. Cardiovascular Diabetology, 2021, 20, 106.	2.7	10
142	Influences on plasminogen activator inhibitor-2 polymorphism-associated recurrent cardiovascular disease risk in patients with high HDL cholesterol and inflammation. Atherosclerosis, 2016, 250, 1-8.	0.4	9
143	Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. Journal of Cardiac Failure, 2016, 22, 143-149.	0.7	9
144	Smoking is associated with an increased risk of first and recurrent ventricular tachyarrhythmias in ischemic and nonischemic patients with mild heart failure: A MADIT-CRT substudy. Heart Rhythm, 2014, 11, 822-827.	0.3	8

#	Article	IF	Citations
145	Changes in Drug Utilization and Outcome With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy. Journal of Cardiac Failure, 2015, 21, 541-547.	0.7	8
146	Effect of Cardiac Resynchronization Therapy in Patients With Insulin-Treated Diabetes Mellitus. American Journal of Cardiology, 2015, 116, 393-399.	0.7	8
147	Scar burden assessed by Selvester QRS score predicts prognosis, not CRT clinical benefit in preventing heart failure event and death: A MADIT-CRT sub-study. Journal of Electrocardiology, 2016, 49, 603-609.	0.4	8
148	Sex Differences in Inappropriate ICD Device Therapies: MADITâ€I and MADITâ€CRT. Journal of Cardiovascular Electrophysiology, 2017, 28, 94-102.	0.8	8
149	Do elevated blood levels of omega-3 fatty acids modify effects of particulate air pollutants on fibrinogen?. Air Quality, Atmosphere and Health, 2018, 11, 791-799.	1.5	8
150	Remote Monitoring of Cardiac Implantable Electronic Devices in Patients Undergoing Hybrid Comprehensive Telerehabilitation in Comparison to the Usual Care. Subanalysis from Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomised Clinical Trial. Journal of Clinical Medicine, 2020, 9, 3729.	1.0	8
151	Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction. Europace, 2020, 22, 1384-1390.	0.7	8
152	Need for pacing in patients who qualify for an implantable cardioverterâ€defibrillator: Clinical implications for the subcutaneous ICD. Annals of Noninvasive Electrocardiology, 2020, 25, e12744.	0.5	8
153	Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure. Cardiology Journal, 2010, 17, 543-8.	0.5	8
154	Implantable cardioverter defibrillator therapy in postinfarction patients. Current Opinion in Cardiology, 2004, 19, 619-624.	0.8	7
155	Identification of Lowâ€Risk Adult Congenital LQTS Patients. Journal of Cardiovascular Electrophysiology, 2015, 26, 853-858.	0.8	7
156	Reduction in Inappropriate ICD Therapy in MADITâ€RIT Patients Without History of Atrial Tachyarrhythmia. Journal of Cardiovascular Electrophysiology, 2015, 26, 879-884.	0.8	7
157	Usefulness of Electrocardiographic Left Atrial Abnormality to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure and Left Bundle Branch Block (a) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	7
158	The prognostic benefit of cardiac resynchronization therapy is greater in concordant vs. discordant left bundle branch block in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Europace, 2018, 20, 794-800.	0.7	7
159	Sex and Genotype in Long QT Syndrome Risk Stratification. JAMA Cardiology, 2019, 4, 254.	3.0	7
160	An aetiologyâ€based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREHâ€HF) trial. ESC Heart Failure, 2021, 8, 1263-1273.	1.4	7
161	Risk Prediction in Women With Congenital Long QT Syndrome. Journal of the American Heart Association, 2021, 10, e021088.	1.6	7
162	Use of oral contraceptives in women with congenital long QT syndrome. Heart Rhythm, 2022, 19, 41-48.	0.3	7

#	Article	IF	Citations
163	Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome. American Journal of Cardiology, 2018, 121, 182-187.	0.7	6
164	Prenatal and recent methylmercury exposure and heart rate variability in young adults: the Seychelles Child Development Study. Neurotoxicology and Teratology, 2019, 74, 106810.	1.2	6
165	Do Ambient Ozone or Other Pollutants Modify Effects of Controlled Ozone Exposure on Pulmonary Function?. Annals of the American Thoracic Society, 2020, 17, 563-572.	1.5	6
166	OUP accepted manuscript. Europace, 2019, 21, 1865-1875.	0.7	6
167	Sex hormones and repolarization dynamics during the menstrual cycle in women with congenital long QT syndrome. Heart Rhythm, 2022, 19, 1532-1540.	0.3	6
168	Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention. JAMA Network Open, 2022, 5, e2217153.	2.8	6
169	Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy. Circulation: Heart Failure, 2022, 15, .	1.6	6
170	Effects of Statins on First and Recurrent Supraventricular Arrhythmias in Patients With Mild Heart Failure (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 457 Td (Resy	0.7	5
171	Temporal Influence of Heart Failure Hospitalizations Prior to Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator on Subsequent Outcome in Mild Heart Failure Patients (from MADIT-CRT). American Journal of Cardiology, 2015, 115, 1423-1427.	0.7	5
172	The Burden and Morphology of Premature Ventricular Contractions and their Impact on Clinical Outcomes in Patients Receiving Biventricular Pacing in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). , 2016, 21, 41-48.		5
173	Heart failure severity, inappropriate ICD therapy, and novel ICD programming: a MADITâ€RIT substudy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1405-1411.	0.5	5
174	Cardiac Magnetic Resonance in Sudden Cardiac Arrest Survivors. Circulation: Cardiovascular Imaging, 2017, 10, e007290.	1.3	5
175	Effects of intranasal kinetic oscillation stimulation on heart rate variability. Annals of Noninvasive Electrocardiology, 2018, 23, e12474.	0.5	5
176	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. Europace, 2019, 21, 1843-1850.	0.7	5
177	A counterpoint paper: Comments on the electrocardiographic part of the 2018 Fourth Universal Definition of Myocardial Infarction endorsed by the International Society of Electrocardiology and the International Society for Holter and Noninvasive Electrocardiology. Annals of Noninvasive Electrocardiology, 2020, 25, e12786.	0.5	5
178	Management of Congenital Long-QT Syndrome: Commentary From the Experts. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009726.	2.1	5
179	Assessment of ECG during hybrid comprehensive telerehabilitation in heart failure patientsâ€"Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREHâ€HF) randomized clinical trial. Annals of Noninvasive Electrocardiology, 2021, 26, e12887.	0.5	5
180	Comparison of Low Versus High (>40Âmm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter Automatic Defibrillator) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td (1053-1058.	0.7	4

#	Article	IF	Citations
181	Cardiac resynchronization therapy is associated with reductions in left atrial volume and inappropriate implantable cardioverter-defibrillator therapy in MADIT-CRT. Heart Rhythm, 2014, 11, 1001-1007.	0.3	4
182	Initiation of dialysis: Trigger or cause of cardiovascular events?. Kidney International, 2015, 88, 942-944.	2.6	4
183	Effect of Significant Weight Change on Inappropriate Implantable Cardioverterâ€Ðefibrillator Therapy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 9-16.	0.5	4
184	Predictors of longâ€term mortality with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. Clinical Cardiology, 2018, 41, 1358-1366.	0.7	4
185	Quantitative Tâ€wave morphology assessment from surface ECG is linked with cardiac events risk in genotypeâ€positive KCNH2 mutation carriers with normal QTc values. Journal of Cardiovascular Electrophysiology, 2019, 30, 2907-2913.	0.8	4
186	Outcome by Sex in Patients With Long QT Syndrome With an Implantable Cardioverter Defibrillator. Journal of the American Heart Association, 2020, 9, e016398.	1.6	4
187	Circadian variation and seasonal distribution of implantable defibrillator detected new onset atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1495-1500.	0.5	4
188	Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trialâ€"Reduce Inappropriate Therapy (MADIT-RIT). Heart Rhythm O2, 2020, 1, 77-82.	0.6	4
189	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): commentâ€"Authors' reply. Europace, 2022, 24, 698-699.	0.7	4
190	Relationship between physical capacity and depression in heart failure patients undergoing hybrid comprehensive telerehabilitation vs. usual care: subanalysis from the TELEREH-HF Randomized Clinical Trial. European Journal of Cardiovascular Nursing, 2022, 21, 568-577.	0.4	4
191	Response to Letter Regarding, â€œPR Interval Identifies Clinical Response in Patients With Non-Left Bundle Branch Block: A Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Sub-Studyâ€•by Kutyifa et al. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1280-1280.	2.1	3
192	Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling. Data in Brief, 2016, 8, 98-104.	0.5	3
193	Population-based beat-to-beat QT analysis from Holter recordings in the long QT syndrome. Journal of Electrocardiology, 2017, 50, 787-791.	0.4	3
194	Right ventricular lead location, right-left ventricular lead interaction, and long-term outcomes in cardiac resynchronization therapy patients. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 185-194.	0.6	3
195	Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved BeyondÂGuidelines for a Defibrillator inÂMADIT-CRT. JACC: Clinical Electrophysiology, 2019, 5, 1172-1181.	1.3	3
196	Cardiac Resynchronization Therapy and Risk of Recurrent Hospitalizations in Patients Without Left Bundle Branch Block. Circulation: Heart Failure, 2020, 13, e006925.	1.6	3
197	Telehealth for the Management of Left Ventricular Assist Device Patients: The University of Rochester TeleLVAD Study. Journal of Cardiac Failure, 2021, 27, 112-113.	0.7	3
198	Utility of cardiovascular implantable electronic deviceâ€"derived patient activity to predict clinical outcomes. Heart Rhythm, 2021, 18, 1344-1351.	0.3	3

#	Article	IF	Citations
199	Genetic Variant Score and Arrhythmogenic Right Ventricular Cardiomyopathy Phenotype in Plakophilin-2 Mutation Carriers. Cardiology, 2021, 146, 763-771.	0.6	3
200	Insulin resistance predicts the risk for recurrent coronary events in post-infarction patients. Cardiology Journal, 2015, 22, 519-526.	0.5	3
201	Markers of ventricular repolarization and overall mortality in sleep disordered breathing. Sleep Medicine, 2022, 95, 9-15.	0.8	3
202	The Relation of QT Dispersion to Spontaneous Ventricular Arrhythmias During the Acute Phase of Myocardial Infarction. Annals of Noninvasive Electrocardiology, 1998, 3, 119-124.	0.5	2
203	Time-Dependent Gender Differences in the Clinical Course of Patients with the Congenital Long-QT Syndrome. , 0, , 28-36.		2
204	Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease. , 2017, 22, e12404.		2
205	Autonomic and Cardiac Repolarization Lability in Long QT Syndrome Patients. Autonomic Neuroscience: Basic and Clinical, 2020, 229, 102723.	1.4	2
206	Which patients with chronic heart failure should be referred for CRT-D implantation? Practical implications of current clinical research. , 2010, 120, 95-102.		2
207	The Clinical Significance of Somatic Pain Tolerance in Patients with Coronary Artery Disease. Annals of Noninvasive Electrocardiology, 1997, 2, 338-345.	0.5	1
208	What to Expect from Electrocardiology at the Beginning of 2000?. Annals of Noninvasive Electrocardiology, 2000, 5, 1-3.	0.5	1
209	Ambulatory ECG Monitoring: 50Years Later. Progress in Cardiovascular Diseases, 2013, 56, 125-126.	1.6	1
210	The QT Scale: A Weight Scale Measuring the QTc Interval. Annals of Noninvasive Electrocardiology, 2017, 22, .	0.5	1
211	Inflammatory markers modify the risk of recurrent coronary events associated with apolipoprotein A-I in postinfarction patients. Journal of Clinical Lipidology, 2017, 11, 215-223.	0.6	1
212	Quantifying Disease Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. JAMA Cardiology, 2017, 2, 303.	3.0	1
213	Effectiveness of high rate and delayed detection ICD programming by race: A MADITâ€RIT substudy. Journal of Cardiovascular Electrophysiology, 2018, 29, 1418-1424.	0.8	1
214	The ST2-SCD score and the conundrum of sudden death prediction in heart failure. International Journal of Cardiology, 2019, 294, 50-51.	0.8	1
215	Prognostic Usefulness of Systolic Blood Pressure One-Year Following Cardiac Resynchronization Therapy (from MADIT-CRT). American Journal of Cardiology, 2020, 125, 777-782.	0.7	1
216	Utility of 6-Minute Walk Test to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure. American Journal of Cardiology, 2020, 132, 79-86.	0.7	1

#	Article	IF	Citations
217	Applicability of the MADIT-CRT Response Score for Prediction of Long-Term Clinical and Arrhythmic Events by QRS Morphology. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008499.	2.1	1
218	Open Access for the Annals of Noninvasive Electrocardiology. Annals of Noninvasive Electrocardiology, 2020, 25, e12737.	0.5	1
219	Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy. Annals of Noninvasive Electrocardiology, 2021, 26, e12847.	0.5	1
220	AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocol. Heart Rhythm O2, 2020, 1, 376-384.	0.6	1
221	Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDISâ€ADONIS trials. Clinical Cardiology, 2022, 45, 101-109.	0.7	1
222	Junctional AV ablation in patients with atrial fibrillation undergoing cardiac resynchronization therapy (JAVA-CRT): results of a multicenter randomized clinical trial pilot program. Journal of Interventional Cardiac Electrophysiology, 2022, 64, 519-530.	0.6	1
223	Counting mRNA in blood of LQTS - new direction?. Kardiologia Polska, 2011, 69, 430.	0.3	1
224	Heart Failure Patientsâ€™ Adherence to Hybrid Comprehensive Telerehabilitation and Its Impact on Prognosis Based on Data from TELEREH-HF Randomized Clinical Trial. Applied Sciences (Switzerland), 2022, 12, 2595.	1.3	1
225	Death in Coronary Artery Disease Patients With Diabetes. JACC: Clinical Electrophysiology, 2021, 7, 1615-1617.	1.3	1
226	Response to Letter Regarding Article, "Syncope in High-Risk Cardiomyopathy Patients With Implantable Defibrillators: Frequency, Risk Factors, Mechanisms, and Association With Mortality: Results From the Multicenter Automatic Defibrillator Implantation Trialâ€“Reduce Inappropriate Therapy (MADIT-RIT) Study". Circulation, 2014, 130, e133.	1.6	0
227	Should We Use Drugs to Decrease Drug-Induced QT Prolongation? âˆ—. JACC: Clinical Electrophysiology, 2016, 2, 775-776.	1.3	0
228	Time Dependence of VentricularÂTachyarrhythmias AfterÂMyocardial Infarction. JACC: Clinical Electrophysiology, 2016, 2, 565-573.	1.3	0
229	T-Wave Morphology in LQTS Patients. JACC: Clinical Electrophysiology, 2017, 3, 382-383.	1.3	0
230	Gender equity imbalance in electrocardiology: A call to action. Annals of Noninvasive Electrocardiology, 2017, 22, .	0.5	0
231	Should we consider the next implantable cardioverter-defibrillator trial in patients with acuteÂcoronary syndrome and monomorphic ventricular tachycardia?. Heart Rhythm, 2018, 15, 830-831.	0.3	0
232	ARTHUR J. MOSS MD. Journal of Cardiovascular Electrophysiology, 2018, 29, 511-513.	0.8	0
233	Arthur J. Moss (1931â€“2018). Annals of Noninvasive Electrocardiology, 2018, 23, .	0.5	0
234	Baseline adverse electrical remodeling and the risk for ventricular arrhythmia in Cardiac Resynchronization Therapy Recipients (MADIT CRT). Journal of Cardiovascular Electrophysiology, 2018, 29, 1017-1023.	0.8	0

#	Article	IF	Citations
235	The role and outcomes of new supraventricular tachycardia among patients with mild heart failure. Journal of Cardiovascular Electrophysiology, 2020, 31, 1099-1104.	0.8	0
236	Marital Status and Long-Term Outcomes in Mild Heart Failure Patients With an Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator. American Journal of Cardiology, 2020, 125, 1180-1186.	0.7	0
237	479 The association of QTc and QT Variability with Severity of Sleep Disordered Breathing. Sleep, 2021, 44, A189-A189.	0.6	0
238	478 The Relationship between Sleep Disordered Breathing, Markers of Ventricular Repolarization and Cardiovascular Mortality. Sleep, 2021, 44, A188-A189.	0.6	0
239	Antiarrhythmic effect of 9-week hybrid comprehensive telerehabilitation and its influence on cardiovascular mortality in long-term follow-up â€“ subanalysis of the TELEREHabilitation in Heart Failure Patients randomized clinical trial. Archives of Medical Science, 2021, 18, 293-306.	0.4	0
240	Hospitalization for HeartÂFailure and Subsequent Ventricular Tachyarrhythmias in Patients With LeftÂVentricular Dysfunction. JACC: Clinical Electrophysiology, 2021, 7, 1099-1107.	1.3	0
241	Prognostic Impact of Hybrid Comprehensive Telerehabilitation Regarding Diastolic Dysfunction in Patients with Heart Failure with Reduced Ejection Fractionâ€”Subanalysis of the TELEREH-HF Randomized Clinical Trial. Journal of Clinical Medicine, 2022, 11, 1844.	1.0	0